AI is more than a technology; it’s a catalyst for deeper insights, faster decisions and stronger collaboration across our teams. In his latest article, Robert Plenge reflects on AI’s impact on R&D, what it means to lead in this new era of collaborative hybrid intelligence and how AI elevates the role of researchers like never before: https://lnkd.in/dJssRwkB #AIAppreciationDay #OneBMS
Just a few years ago, AI in drug discovery felt like a futuristic concept – something we were preparing for, but not yet practicing. Today, that future is here. AI has become an essential part of how we do science by empowering us to ask better questions and make smarter decisions. While AI brings significant value across the R&D continuum, I’m particularly excited by its profound impact at the front end of R&D. At Bristol Myers Squibb, we’re applying AI to help us: 🎯 Select targets with the strongest causal human biology 🧩 Match the right modality ➡️ Bridge the gap to development with a clearer path to clinical proof of concept In my latest piece, I reflect on leading a research organization in this new era of collaborative hybrid intelligence, with people and algorithms working together to bring transformational therapies to those who need them most. #AIAppreciationDay #BMS_Employee
Clarity in AI
11h
Great read on the evolving role of AI in research. Love the focus on hybrid intelligence blending human expertise with machine insights is how real breakthroughs happen.
This is a key point regarding AI in R&D. Its effectiveness is deeply reliant on the quality of the data, the precision of the questions asked, and the application of strong scientific judgment. When these elements are in place, AI can significantly expand possibilities and guide design choices, ultimately improving therapeutic success.
Agreed! AI isn’t just accelerating R&D, it’s transforming how researchers collaborate and discover. Great to see BMS leading the way with a thoughtful, human-centered approach to hybrid intelligence! 👏